CB 2 receptors, the so-called peripheral cannabinoid receptor type, were first described in the immune system, but they have been recently identified in the brain in healthy conditions and, in particular, after several types of cytotoxic stimuli. Specifically, CB 2 receptors were identified in microglial cells, astrocytes and, to a lesser extent, in certain subpopulations of neurons. Given the lack of psychoactivity demonstrated by selective CB 2 receptor agonists, this receptor becomes an interesting target for the treatment of neurological diseases, in particular, the case of certain neurodegenerative disorders in which induction/up-regulation of CB 2 receptors has been already demonstrated. These disorders include Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis and others. Interestingly, in experimental models of these disorders, the activation of CB 2 receptors has been related to a delayed progression of neurodegenerative events, in particular, those related to the toxic influence of microglial cells on neuronal homeostasis. The present article will review the evidence supporting that CB 2 receptors might represent a key element in the endogenous response against different types of cytotoxic events, and that this receptor type may be a clinicallypromising target for the control of brain damage in neurodegenerative disorders.
the brain although also present in the periphery, first called cannabinoid receptor and lately CB 1 receptor, whose activation is directly related to the psychoactivity typical of certain plant-derived cannabinoids (Pertwee, 2005) . However, this is not the only receptor that may be activated by cannabinoids. In 1993, Munro and coworkers (Munro et al., 1993) cloned a second cannabinoid receptor type, the so-called CB 2 receptor, that is not involved in psychoactive effects of cannabinoids and, accordingly, it was initially found in the periphery, particularly in immune cells (for a recent review, see Raitio et al., 2005) . This "peripheral cannabinoid receptor" is located in chromosome 1p36 in the human and encodes a protein of 360 amino acids with a 44% homology with the CB 1 receptor, although the homology is greater in the transmembrane domain (approximately 68%).
CB 2 receptor: pharmacological characteristics
The pharmacology of CB 2 receptors is in part similar to CB 1 receptors (e.g. most plantderived and synthetic cannabinoid agonists activate CB 2 receptors), although the affinity and/or potency at which these agonists bind and/or activate CB 2 receptors present some interesting differences compared to CB 1 receptors (Pertwee, 2005; Fernández-Ruiz et al., 2007) . This also happens in the case of endocannabinoid ligands, since anandamide (arachidonoylethanolamide, AEA) was reported to be a weaker agonist for CB 1 receptors and not to significantly bind to CB 2 receptors (Mechoulam and Hanus, 2000; Sugiura et al., 2006) , except in pathological conditions (Eljaschewitsch et al., 2006) , whereas several studies suggested that 2-arachidonoylglycerol (2-AG) is an endogenous agonist for CB 2 receptors (Sugiura et al., 2006 ). It appears obvious that these pharmacological differences are the consequence, among others, of certain differences in chemical structures of cannabinoid agonists, differences that have been used to design selective synthetic CB 2 receptor agonists. This is the case of compounds such as JWH-133 and their analogs (Huffman, 2005) , HU-308 (Hanus et al., 1999) and AM1241 (Malan et al., 2001) , which represent novel tools to activate Page 4 of 16 A c c e p t e d M a n u s c r i p t 4 selectively CB 2 receptors without the concomitant activation of the CB 1 receptor type. This represents an important goal since, although cannabinoids have a favorable drug safety profile, their use in the clinic is severely limited by the psychoactive effects elicited by most of cannabinoid agonists and mediated by the activation of CB 1 receptors. Therefore, an attractive alternative is to target CB 2 receptors selectively with the above-described agonists which are completely devoid of psychoactive effects, although they might exhibit other side effects such as immune suppression (Pertwee, 2005) . Their potential for the treatment of certain neurological diseases is presently being examined in multiple preclinical studies, including several neuroinflammatory/neurodegenerative disorders in which CB 2 receptor agonists might serve to delay the progression of neuronal damage , for a recent review). On the other hand, selective antagonists for the CB 2 receptor are also currently available, and constitute important tools to elucidate the involvement of this receptor type in specific cellular functions (for review, see Pertwee, 2005; . CB 2 receptor: tissue and cell distribution As mentioned above, the first studies that explored the tissue and cell distribution of CB 2 receptors indicated that this cannabinoid receptor type was exclusively present in tissues and cells of the immune system (e.g. spleen macrophages, tonsils, B cells and natural killer cells, monocytes, neutrophils and T cells; Howlett et al., 2002; Pertwee, 2005; Fernández-Ruiz et al., 2007, for review) , being absent from the CNS (Lynn and Herkenham, 1994) , in notable contrast with the well-known distribution of CB 1 receptors. Further studies suggested that, although absent from the CNS in normal conditions, this receptor might be induced in glial cells, in particular reactive microglia, in response to different damaging conditions associated with local inflammatory events (see Fernández-Ruiz et al., 2007, for review) . Lastly, recent studies have proposed that CB 2 receptors may be present in the brain even in healthy conditions (Onaivi et al., 2006) , despite this issue has remained controversial due to uncertainty of experimental approaches used or of some methodological tools available (e.g.
anti-CB 2 antibody). These studies identified CB 2 receptors in glial cells, including microglia and astrocytes (Stella, 2004; Nuñez et al., 2004; Maresz et al., 2005) , neural (Palazuelos et al., 2006) and oligodendroglial (Molina-Holgado et al., 2002) progenitors, and certain neuronal subpopulations (Skaper et al., 1996; Ross et al., 2001; Stander et al., 2005; Wotherspoon et al., 2005; Van Sickle et al., 2005; Beltramo et al., 2006) CB 2 receptor: signaling mechanisms CB 2 receptors belong to the seven-transmembrane domain, G-protein-coupled receptor class (Howlett et al., 2002) . They are coupled to G i/o proteins, so that their activation, in various cell types expressing the receptor either naturally or heterologously, is associated with classic intracellular responses: (i) the inhibition of adenylyl cyclase and the cAMP/protein kinase A (PKA)-dependent pathway (Howlett et al., 2002) ; and (ii) the stimulation of mitogenactivated protein kinase (MAPK) cascades, specifically the extracellular signal-regulated kinase (ERK) (Bouaboula et al., 1996; Carrier et al., 2004; Palazuelos et al., 2006) and the p38 MAPK cascades (Gertsch et al., 2004; Herrera et al., 2005) . In addition, the activation of CB 2 receptors has been also linked to the stimulation of additional intracellular pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Molina-Holgado et al., 2002; Samson et al., 2003; Palazuelos et al., 2006) , which has been associated with prosurvival effects, and the de novo synthesis of the sphingolipid messenger ceramide (Sánchez et al., 2001; Carracedo et al., 2006a and 2006b) , which has been linked with the pro-apoptotic effects of cannabinoids.
CB 2 receptor and neuroprotection
Most of physiological functions associated with the CB 2 receptor deal with different types of immunological effects given the predominance of this receptor type over the CB 1 receptor in immune tissues. However, its recent description in certain brain regions allowed relate this receptor type to those neurobiological processes located in those region, for example, the control of pain, brain reward, emotion and others (Onaivi et al., 2006, for review) . An important point is the implication of the CB 2 receptor in processes related to the control of proliferation (Carrier et al., 2004; Palazuelos et al., 2006) , differentiation (Sánchez et al., 2001; Alberich Jorda et al., 2004; Palazuelos et al., 2006) and survival (Sánchez et al., 2001) of neural cells. That the CB 2 receptor plays a role in these key cell processes is the basis for the proposal that selective agonists of this receptor type may act on "two sides of a coin" by providing cytoprotection of healthy neural cells or by eliciting apoptosis of tumoral cells (see Fernández-Ruiz et al., 2007 , for a recent review). This review will focus only in the first of M a n u s c r i p t (Benito et al., 2003) and in an experimental model of AD in rats (Esposito et al., 2007) ; (vi) in a rat model of neuropathic pain (Zhang ey al., 2003) ; (vii) in patients with MS (Yiangou et al., 2006; Benito et al., 2007) and in an experimental model of MS in mice (Maresz et al., 2005) ;
and (viii) also in patients with ALS (Yiangou et al., 2006) . This up-regulatory response of CB 2 receptors would be paralleled in some cases by equivalent responses of CB 1 receptors and endocannabinoid ligands . Therefore, one may 
Control of glial-mediated effects by CB 2 receptors
Given that CB 2 receptors that provide neuroprotection in neurodegenerative disorders (see above section) seem to be those that are induced/up-regulated in glial cells in response to damaging stimuli, it appears likely to assume that their function within the endogenous protection against these stimuli would be related to limiting the toxic influence of microglia on neuronal homeostasis, to enhancing the protection exerted by astrocytes, or both. For instance, astrocytes have been reported to function as "neuroprotective cells" by generating pro-survival factors (e.g. neurotrophins) or metabolic substrates (e.g. ketone bodies, lactate) M a n u s c r i p t 8 for neurons (see Chen and Swanson, 2003 for review) . CB 2 receptors have been identified in these glial cells at lesioned sites . Therefore, it is possible that these receptors might enhance the generation of pro-survival factors or the support of metabolic substrates (see Figure 1 for an overview), but this possibility has not been determined yet. By contrast, microglial cells are recruited in response to brain injury and migrate at lesioned sites where they might play a primary "protective" function but that secondarily becomes toxic for neurons. It has been proposed, and demonstrated in a series of elegant studies (Puffenbarger et al., 2000; Facchinetti et al., 2003; Stella, 2004) , that, in microglia, the up-regulatory response of CB 2 receptors would be aimed at controlling the processes of proliferation, differentiation and migration of these cells (Walter et al., 2003; Carrier et al., 2004) , as well as at limiting the magnitude of neurotoxic response exerted by microglial cells . According to this, the activation of CB 2 receptors would reduce the generation of neurotoxic factors, such as nitric oxide, proinflammatory cytokines and reactive oxygen species, by these reactive glial cells (see 
Closing remarks
The studies reviewed here strongly support that brain CB 2 receptors are important players in the control of neuroinflammatory events associated with conditions of brain damage of different etiologies. In pathological conditions, CB 2 receptors are induced in cells that do not contain these receptors in healthy conditions (e.g. reactive microglia) or are up-regulated in cells that do contain a small number of these receptors. These responses are likely part of an endogenous mechanism of defense against a variety of brain-damaging insults, where they appear associated with equivalent responses in other elements of the cannabinoid signaling.
Through the activation of these receptors, either in reactive microglial cells or in astrocytes, cannabinoid agonists might limit the toxic influence of microglia on neuronal homeostasis or potentiate the metabolic support exerted by astrocytes. Both effects, occurring independently A c c e p t e d M a n u s c r i p t 9 or concomitantly, may enhance the possibilities of neuronal survival, so that this receptor represents a clinically-promising target for delaying/arresting the progression of neurodegeneration in acute and, in particular, in chronic neurological disorders.
M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t receptors are located in reactive microglia and astrocytes and they play a role in the endogenous response against neurodegenerative/neuroinflammatory stimuli.
• more neurotrophins?
• more metabolic substrates (ketone bodies, lactate)?
